<DOC>
	<DOCNO>NCT00465816</DOCNO>
	<brief_summary>This study demonstrate non-inferiority GSK Biologicals ' meningococcal vaccine 134612 give experimental co-administration versus vaccine 134612 alone versus experimental co-administration alone healthy subject age 11 17 year . There 3 group study .</brief_summary>
	<brief_title>Primary Study Demonstrate Non-inferiority Immunogenicity GSK Biologicals ' Meningococcal Vaccine 134612</brief_title>
	<detailed_description>All subject group A B 4 blood sample take , subject group C 3 blood sample take . The Protocol Posting update order comply FDA Amendment Act , September 2007 .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/guardians comply requirement protocol A male female , include , 11 17 year age time first dose vaccine . Written inform consent obtain subject/ parent guardian subject . Healthy subject establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her/the parents'/guardians ' knowledge . If subject female childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W135 and/or Y within last five year . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C , W135 and/or Y . Previous vaccination tetanus toxoid within last month . Previous vaccination hepatitis A and/or hepatitis B vaccine . Seropositivity hepatitis A IgG , hepatitis B surface antigen , hepatitis B core antibody and/or hepatitis B surface antigen screen . History hepatitis A , hepatitis B and/or Neisseria meningitidis infection . Known exposure hepatitis A and/or hepatitis B virus within three month precede first dose study vaccine . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History reaction allergic disease likely exacerbate component either vaccine . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>non-inferiority</keyword>
	<keyword>adolescent</keyword>
	<keyword>meningococcal vaccine</keyword>
</DOC>